SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Omeros
An SI Board Since March 2010
Posts SubjectMarks Bans Symbol
464 28 0 OMER
Emcee:  Bradpalm1 Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
414I call BS on that lack of need to raise money. Total BS, and that writer does nBiotech Jim16/24/2017
413OMEROS 2017 REVENUES & CASH NEEDS: NO SECONDARY REQUIRED ww.trustintelligenHoward Williams-6/24/2017
412I sent this note below to my syndicate shortly after my initial post: "AftBiotech Jim-6/23/2017
411Jim: It's my understanding that S-8s are often filed by companies to registeBulbaMan-6/23/2017
410Omeros S8 filing on 06 21 2017: investor.omeros.com This is quite interesting,Biotech Jim-6/22/2017
409Congrats, Howard! As a long time Omeros booster you deserve every one of those pBulbaMan16/21/2017
408$26.58 is a record close by more pennies than all my (and my wife's!) fingeHoward Williams-6/21/2017
407 [graphic] [graphic]The Ox-6/20/2017
406Looking good ........ OMER continues showing strength this morning, suggesting Howard Williams-6/20/2017
405Thanks to a Yahoo poster ....... fool.com 3 Stocks Wall Street Hasn't NotiHoward Williams-6/17/2017
404OMEROS IS GREAT FOR PATIENTS, BUT NOT FOR ALEXION by Alan Robert Ross, Ph.D. TruHoward Williams-6/15/2017
403Favorable Omidria article published ncbi.nlm.nih.gov J Cataract Refract Surg. 2Howard Williams-6/15/2017
402Here's something else that can goose OMER higher near term BREAKTHROUGH THHoward Williams-6/14/2017
401Yes. Both names unchanged for many, many years. :-)Howard Williams16/13/2017
400Are you Dooper?Biotech Jim-6/13/2017
399I am guessing that OMS721 could see approval for IgAN in what would be a record Howard Williams-6/13/2017
398Kidney immuno-inflammatory diseases is my reason for liking OMS721, as previouslBiotech Jim-6/13/2017
397Looking quite good here for higher prices. [graphic]hollyhunter-5/18/2017
396Also, there’s the potential that today’s reported results will be the catalyst fBulbaMan-5/17/2017
395>>In nephropathy, as one OMS721 example, what will be the number of Ph3 trHoward Williams15/17/2017
394I used the price spike opportunity to sell some shares, these were at a double. Biotech Jim35/17/2017
393Omeros Announces Completion of IgA Nephropathy Cohort in OMS721 Phase 2 ClinicalHoward Williams-5/17/2017
392Their was a blurb "The Street" this morning by Cramer recommending toD.Lu14/6/2017
391I made a PDF of the slide deck from yesterdays presentation and the cowen one inghmm-4/6/2017
390Omeros slide deck for Needham Conference: seekingalpha.comBulbaMan-4/5/2017
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News